Happy NY to all. Madam - suggest you speak to the company if you...

Happy NY to all.
Madam - suggest you speak to the company if you want clarification.
But your discussion about prioritising Tier 1 applications is on point and this is where the resources are being allocated.

Approx 2-3 years back, I spoke to Paul Simmons (one of the original Adelaide Uni inventors and now head of Research & New Product Development). At the time of speaking with him he had just moved from M.D. Anderson Cancer to MSB where his previous role was working alongside The Principle investigator Elizabeth Shpall in regards to the Cord Blood Expansion on Mesenchymal Stem Cells 125 patient P1 Trial. What he did say to me at the time was that the MPC technology created massive excitement at the M.D Anderson Cancer Centre due to its potential impact on patients.
This study completed recruitment on 2 Nov 2015, with July 2017 being the date for Final data collection date for primary outcome measure.

https://clinicaltrials.gov/ct2/show/NCT00498316?term=mesenchymal+stem+cells+and+bone+marrow+transplant&rank=145
On the basis of the P1 trial a new 240 patient P3 trial was initiated in May 2013 and last updated on 28 July 2015. The trial is currently recruiting patients at 9 sites (1 completed).
https://clinicaltrials.gov/ct2/show/NCT01854567?term=mesoblast&rank=2
Whilst its not a huge application (mkt size..makes sense to make it Tier 2) , it does have Orphan Drug status designation and my personal view is one that could surprise the market in due course.
Now what happened in 2013(and then effectively 2014) that made MSB prioritise its applications into Tier 1,2, other ? They acquired Osiris.
Outside of the deal made with Hanson Institute & Angioblast, this was a master call by SI and 2016 is shaping up as the year that this investment will take centre stage.
Temcell now approved with US $113m - $170m agreed reimbursement . Bodes well for the 60 patient US GVHD trial currently recruiting with interim efficacy date in ~Sept 16 QRT. Vinny previously posted that Ladenberg hosted a “KOL discussion at the American Society of Hematology meeting with Duke University Professor, Joanne Kurtzberg, to discuss the outlook of acute graft-versus-host disease (aGVHD) therapies and potential outlook for MESO's remestemcel-L program for the treatment of steroid refractory pediatric aGVHD ’’. [12/12/15 10.58am – worth reading again to understand the medium term opportunity that this application presents and why elated to Tier 1].
Looking forward to upcoming JP Morgan conference (11th - 14th Jan 16). Meso - one of the few Aus companies again invited to one of the major health conferences of the year.
Please DYOR and GLTAH